$MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ร agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
William J. Sibold
CEO
528
Employees
$534.49
Current Price
$10.55B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 10 | $2,831,800.73 | 5,221 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 24 | $6,239,198.15 | 11,583 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 24 | $6,239,198.15 | 11,583 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 35 | $7,949,391.68 | 14,747 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 35 | $7,949,391.68 | 14,747 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: